Janssen

XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B
XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B
Seeking Alpha
Xbiotech
JNJ
Janssen
bermekimab
Flag link:
Janssen taps wearable tech in Invokana heart failure trial
Janssen taps wearable tech in Invokana heart failure trial
Pharmaforum
JNJ
Janssen
Invokana
heart failure
wearables
real world evidence
clinial trials
Flag link:
Janssen’s Stelara Wins FDA Approval for Ulcerative Colitis
Janssen’s Stelara Wins FDA Approval for Ulcerative Colitis
BioSpace
JNJ
Janssen
Stelara
FDA
ulcerative colitis
Flag link:
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
BioSpace
JNJ
Janssen
Tremfya
clinical trials
psoriasis
Flag link:
J&J Will Appeal $8 Billion Verdict of Claims Risperdal Caused Breast Growth
J&J Will Appeal $8 Billion Verdict of Claims Risperdal Caused Breast Growth
BioSpace
JNJ
Janssen
Risperdal
Flag link:
J&J adds 200 jobs with new biopharma plant at site in Ireland
J&J adds 200 jobs with new biopharma plant at site in Ireland
Fierce Pharma
JNJ
Janssen
Ireland
drug manufacturing
hirings
Flag link:
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics
Marketwatch
JNJ
Janssen
tuberculosis
HIV
philanthropy
Flag link:
Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients
Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients
BioSpace
Erleada
Janssen
JNJ
ESMO
prostate cancer
Flag link:
Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO
Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO
Fierce Biotech
gene therapy
Passage Bio
Janssen
Flag link:
Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed
Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed
Drug Channels
Eli Lilly
Janssen
Merck
Novartis
Sanofi
drug pricing
Flag link:
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Janssen’s MS pill outshines Sanofi’s Aubagio in phase 3 trial
Pharmaforum
JNJ
Janssen
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
J&J gets Stelara okay in Europe for ulcerative colitis
J&J gets Stelara okay in Europe for ulcerative colitis
Pharmaforum
JNJ
Stelara
Janssen
Europe
Flag link:
Companies file suit in Canada challenging new rules to lower drug prices
Companies file suit in Canada challenging new rules to lower drug prices
Yahoo/Reuters
drug pricing
Canada
Janssen
Merck
Bayer
Servier
Boehringer Ingelheim
Flag link:
Janssen gets EC approval for two new indications of Imbruvica
Janssen gets EC approval for two new indications of Imbruvica
Pharmaceutical Business Review
JNJ
Janssen
Europe
Imbruvica
Waldenström’s macroglobulinemia
chronic lymphocytic leukemia
Flag link:
Janssen returns rights for experimental cancer immunotherapy to Alligator Bioscience, sending shares spiraling by 40%
Janssen returns rights for experimental cancer immunotherapy to Alligator Bioscience, sending shares spiraling by 40%
Pharmaceutical Business Review
Janssen
Alligator Biosciences
CD40
cancer immunotherapy
Flag link:
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
BioSpace
Janssen
JNJ
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
FDA quickly approves J&J’s Darzalex in multiple myeloma
FDA quickly approves J&J’s Darzalex in multiple myeloma
Pharmaforum
JNJ
Janssen
FDA
Darzalex
Multiple Myeloma
Flag link:
Time to fix pharma’s outdated business model
Time to fix pharma’s outdated business model
Pharmaforum
pharma industry
payers
patients
Janssen
Flag link:
Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials
Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials
Pharmaceutical Business Review
JNJ
Janssen
Tremfya
clinical trials
psoriatic arthritis
Flag link:
Janssen Eyes Another Approval for Tremfya After Hitting Trial Endpoints
Janssen Eyes Another Approval for Tremfya After Hitting Trial Endpoints
BioSpace
JNJ
Janssen
clinical trials
Tremfya
psoriatic arthritis
Flag link:

Pages